IR-News

AUSSENDER



SANOCHEMIA Pharmazeutika AG
Ansprechpartner: Bettina Zuccato
Tel.: +43 1 3191456-336
E-Mail: b.zuccato@sanochemia.at

FRüHERE MELDUNGEN

11.07.2019 - 09:16 | SANOCHEMIA Pharmazeutika AG
02.07.2019 - 08:00 | SANOCHEMIA Pharmazeutika AG
02.07.2019 - 08:00 | SANOCHEMIA Pharmazeutika AG
19.06.2019 - 08:51 | SANOCHEMIA Pharmazeutika AG
12.06.2019 - 09:26 | SANOCHEMIA Pharmazeutika AG
pta20190711008
Business news for the stock market

SANOCHEMIA Pharmazeutika AG: European patent granted for Vidon® in photodynamic diagnostics


Wien (pta008/11.07.2019/09:18) - Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307, ISIN DE000A1G7JQ9), announces that the European Patent Office positively completed the examination procedure for the patent application of Vidon® in the Photodynamic Diagnosis (PDD) of bladder cancer.

Vidon® (PVP-Hypericin) is being developed as a game changing technology in the treatment of bladder cancer. The patent covers an improved bladder cancer detection technique with the PVP Hypericin formulation developed by SANOCHEMIA. The patent will protect Vidon® in the PDD until 2035.

"Due to the positive decision of the European Patent Office, the patent portfolio for Vidon® has been broadened. Sanochemia's technology is patent protected in Europe and the US over many years; this creates an important prerequisite for the long term value of Vidon®." Christina Abrahamsberg, CSO.
-------------------------------------------------- -------------------------------------------------- ---
Bladder cancer is the most common malignancy of the urinary tract. Approximately 75% of the initially diagnosed bladder cancers are non- muscle invasive tumors, which means that the tumor is restricted to the mucosa. In 30-80% of the patients, recurrences occur, requiring repeated surgeries. About 45% of bladder cancers will progress to a muscle invasive bladder carcinoma.
Early detection, timely and appropriate treatment are therefore essential factors for improving the prognosis of urinary bladder carcinoma patients.
Vidon® is being developed by Sanochemia Pharmazeutika AG as a diagnostic and therapeutic option for patients with non-muscle invasive tumors.

(end)
emitter: SANOCHEMIA Pharmazeutika AG
Boltzmanngasse 11
1090 Wien
Austria
contact person: Bettina Zuccato
phone: +43 1 3191456-336
e-mail: b.zuccato@sanochemia.at
website: www.sanochemia.at
stock exchanges: free market in Dusseldorf, basic board in Frankfurt, free market in Hamburg, free market in Munich, free market in Stuttgart; direct market plus in Vienna; open market in Berlin
ISIN(s): AT0000776307 (share)
|
|
98.209 Abonnenten
|
175.662 Meldungen
|
71.260 Pressefotos

BUSINESS

18.11.2019 - 12:30 | pressetext.redaktion
18.11.2019 - 06:05 | pressetext.redaktion
16.11.2019 - 16:05 | OMF Online-Marketing-Forum.at GmbH
15.11.2019 - 13:30 | pressetext.redaktion
15.11.2019 - 12:10 | Heemann Vermögensverwaltung AG
Top